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Dendritic cells (DCs) are highly specialized antigen-presenting cells that play cru-
cial roles in innate and adaptive immunity. Previous studies suggested that Toll-like 
receptor (TLR) agonists could be used as potential adjuvants, as activation of TLRs can 
boost DC-induced immune responses. TLR2 agonists have been shown to enhance
DC-mediated immune responses. However, classical TLR2 agonists such as Pam3CSK4 
are not stable enough in vivo, which limits their clinical applications. In this study, a novel 
structurally stable TLR2 agonist named SUP3 was designed. Functional analysis showed 
that SUP3 induced much stronger antitumor response than Pam3CSK4 by promoting
cytotoxic T lymphocytes activation in vivo. This effect was achieved through the following 
mechanisms: SUP3 strongly enhanced the ability of antigen cross-presentation by DCs 
and subsequent T cell activation. SUP3 upregulated the expression of costimulatory
molecules on DCs and increased antigen deposition in draining lymph nodes. More
interestingly, SUP3 induced less amount of pro-inflammatory cytokine production in vivo 
compared to other TLR agonists such as lipopolysaccharide. Taken together, SUP3
could serve as a novel promising immune adjuvant in vaccine development and immune 
modulations.
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inTrODUcTiOn
The agonists of Toll-like receptors (TLRs) especially recognized by dendritic cells (DCs) promote 
activation of innate immunity and help initiate adaptive immune responses. These TLR agonists 
thus can be applied as immune adjuvants to enhance DC-mediated vaccination and cancer immu-
notherapy (1, 2). Currently, some TLR agonists, such as TLR4 agonist monophosphoryl lipid A 
(MPL), have been licensed to be used as adjuvants in vaccination and approved (at least in some 
Abbreviations: CFSE, carboxyfluorescein diacetate, succinimidyl ester; CTL, cytotoxic T lymphocyte; DC, dendritic cell; 
GM-CSF, granulocyte-macrophage colony-stimulating factor; LPS, lipopolysaccharide; MAPK, mitogen-activated protein 
kinase; MHC, major histocompatibility complex; NP-KLH, nitrophenyl-keyhole limpet hemocyanin; OCS, OVA-coated 
splenocytes; OVA, ovalbumin; PBS, phosphate buffered saline; TD antigen, thymus-dependent antigen.
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countries) in oncological conditions (3–7). TLR2 is a conserved 
molecule expressed by both murine and human conventional 
DCs (cDCs), and TLR2 agonists have been shown to have great 
potential to be utilized as adjuvants to enhance cDC-mediated 
immune responses (8). However, until now TLR2 agonists have 
not been approved as clinical adjuvants, possibly due to their poor 
stabilities and thus weak potency in vivo (1, 2, 9). It is therefore 
desirable to design new TLR2 agonist, if it would be used as an 
adjuvant in immunotherapy.
Innate immunity represents the first line of defense against 
invading pathogens. Innate immune cells like DCs sense dan-
ger signals and initiate responses against them. As the most 
efficient antigen-presenting cells (APCs), cDCs are in charge 
of recognizing antigens and promoting adaptive immunity 
through activation of naïve T cells (10, 11). Stimulation of DC 
upon recognition of antigens via multiple pattern recognition 
receptors (PRRs) upregulates the expression of costimulatory 
molecules and induces the production of various cytokines and 
chemokines, contributing to T cell activation and inflammatory 
responses. Therefore, DCs bridge innate and adaptive immunity 
and play pivotal roles in orchestrating immune responses (12). 
Murine splenic DCs are heterogeneous populations consisting 
of CD8+ cDCs, CD11b+ cDCs, and plasmacytoid DCs (pDCs) 
(13, 14). CD8+ cDCs are specialized in antigen cross-presentation 
via major histocompatibility complex (MHC)-I to activate CD8+ 
T cells and ultimately differentiate them into cytotoxic T lym-
phocytes (CTLs), suggesting CD8+ cDCs as essential initiators of 
cellular immunity. Moreover, CD8+ cDCs can polarize CD4+ T 
cells into Th1 phenotype by direct antigen presentation through 
MHC-II pathway and by producing IL-12p70. The CD11b+ cDCs 
mainly uptake exogenous antigens and directly present them to 
CD4+ T cells via MHC-II to induce differentiation of multiple 
subsets of helper T cells, including Th2 and Th17, which are cru-
cial in defense against extracellular pathogens like parasites and 
bacteria (15). In contrast, pDCs are characterized by secreting 
large amount of type I interferons (IFNs) upon viral infection, 
but have limited antigen presentation ability. The heterogene-
ity of DCs highlights the concept of division of labor through 
functional specialization of DC subsets (15).
Pathogen-associated molecular patterns induce functional 
maturation of immune cells through binding on specific PRRs 
and enhancing the cellular functions. For instance, ligation of 
TLR on DCs effectively program DCs into an active status and 
dramatically enhance DC functions. Therefore, TLR agonists are 
widely used as stimulators of DCs and enhancers of DC-mediated 
immune responses (2, 16, 17). TLR2 is a special member among 
TLR families that needs to form heterodimers with TLR1 or 
TLR6 to recognize triacyl (Pam3CSK4) or diacyl (Pam2CSK4) 
lipopeptides, respectively (18, 19). Cell surface receptor TLR2 
recognizes lipopeptides mainly derived from cell wall components 
of bacteria to elicit innate signaling events. TLR2 represents one 
of important sensors to pathogens and TLR2 deficiency impairs 
host defense against bacterial infection (20, 21). As TLR2 is con-
served in mouse cDCs and their human counterparts, especially 
between murine CD8+ cDCs and the human equivalent CD141+ 
cDCs (22), agonists targeting TLR2 could be promising adju-
vants in designing vaccines through activating DCs for cancer 
immunotherapy. Previous studies showed that conjugation of 
antigens and TLR agonists targeting APCs achieved dramatically 
more potent responses than combination of antigens and TLR 
agonists (23–26). Unlike other TLR ligands, the intrinsic peptide 
component of TLR2 ligands provides the possibility to directly 
conjugate antigenic peptides within TLR2 agonists. Notably, the 
expression of TLR2 by DCs, providing the potential for using 
TLR2 agonists as adjuvants in DC-mediated immune responses, 
and so far increasing number of TLR2 agonists have been devel-
oped (24, 27–30).
Recently, it has been reported that TLR2 agonists could be 
used directly (31–34) or as structurally modified forms (26) in 
cancer treatment, suggesting that TLR2 agonists can be potential 
effective enhancers for cancer immunotherapies. Administration 
of TLR2 agonists could enhance effector and memory T cell 
responses, leading to elevated efficacy of vaccination and tumor 
rejection (24, 30, 31, 33, 35). Moreover, TLR2 agonists could sen-
sitize B cell lymphoma to chemotherapeutic agents via upregulat-
ing costimulatory molecules to increase their sensitivity to NK 
cell and CTL cytotoxicity (32), or inducing caspase 8-dependent 
apoptosis (34). These facts have made TLR2 agonists to be attrac-
tive adjuvants in the therapy of cancers (28, 30, 35). However, 
current available TLR2 agonists have limited applications due 
to their rapid degradation in plasma where abundant esterase 
exists, which breaking ester bonds connecting glycerol backbone 
and palmitic acid chains, resulting in diminished stimulation of 
TLR2. Hence, it is necessary to develop new TLR2 agonists with 
higher stability in  vivo and can be further utilized as immune 
adjuvants.
In this study, we designed a new TLR2 agonist termed SUP3 
based on the structure of Pam3CSK4 (Pam3 hereafter), which is 
a chemically more stable ligand for TLR2/TLR1 heterodimers. 
Functional analysis revealed that SUP3 had stronger capabilities 
than Pam3 in DC-mediated activation of CTL and T-dependent 
antibody production. Further studies of its activity and effects 
on immune responses showed that SUP3 enhanced antigen 
presentation ability of cDCs and subsequent T cell activation 
without leading to excessive inflammatory responses. Our studies 
demonstrated that SUP3 could function as a potential immune 
adjuvant in vaccination and immunotherapy.
MaTerials anD MeThODs
Mice
C57BL/6 mice were maintained in a specific pathogen-free 
facility at Tsinghua University. OT-I and OT-II transgenic mice 
were purchased from Jackson Laboratory. Mice were sacrificed 
at the age of 6~8 weeks for experiments. The experiments using 
mice were approved by the Institutional Animal Care and Use 
Committees at Tsinghua University.
generation of Tlr2−/− raW 264.7 cells
Tlr2−/− RAW 264.7 cells were generated by lentiviral CRISPR-
Cas9 system as described previously (36). Briefly, target guide 
sequences (5′-CACCGCCTGGAGGTTCGCACACGCT-3′, 
3′-CGGACCTCCAAGCGTGTGCGACAAA-5′) designed by 
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Genome Engineering 3.0 were ligated into lentiviral vector 
lentiCRISPR (Addgene 52961). Then lentiCRISPR as well as 
packaging plasmids pMD2.G (Addgene 12259) and psPax2 
(Addgene 12260) were co-transfected into 293FT cells by CaCl2 
(12.5 mM) for virus packaging. Fresh cell culture medium was 
changed 12 h post-transfection. After another 72 h, 293FT cell 
culture supernatant containing virus was harvested, filtered, and 
concentrated. Then, RAW 264.7 cells were infected by the virus 
(~5 × 105 TU/mL) with the presence of 8 µg/mL polybrene (Sigma 
H9268). After that, puromycin (4  µg/mL; Sigma P7255) was 
added to select positive cells for 48 h post-viral infection. TLR2 
depletion efficiency of Tlr2−/− RAW 264.7 cells was examined 
by flow cytometry using a PE conjugated anti-TLR2 antibody 
(eBioscience, clone 6C2).
Flow cytometry
Single cell suspensions were prepared, and cells were stained 
by fluorescence-conjugated antibodies and viability dye 7-AAD 
(eBioscience 00-6993) at 4°C for 30 min in the dark. Cells were 
washed, resuspended, and analyzed on LSR Fortessa (Becton 
Dickinson). FACS data were analyzed and displayed by FlowJo 
software (Tree Star).
isolation of splenic Dcs and B cells
Splenic DCs were purified as described previously (37). CD8+ 
cDCs expanded by B16-Flt3L inoculation were enriched, and 
then CD8+ cDCs were positively sorted by MACS technol-
ogy (Miltenyi Biotec). Splenic B cells were purified through 
negative selection by Streptavidin-MicroBeads (Miltenyi Biotec 
130-048-102) combined with different antibodies cocktail to 
exclude non-B cells. The antibodies cocktail was composed of 
biotinylated antibodies against CD4 (T cells and DCs) (eBiosci-
ence, clone GK1.5), CD8 (T cells and DCs) (eBioscience, clone 
53-6.7), CD43 (T cells, monocytes, granulocytes) (eBioscience, 
clone eBioR2/60), and Ter119 (erythrocytes) (eBioscience, clone 
TER119). B cells were further purified through MACS LS column 
(Miltenyi Biotec 130-042-401).
antigen Presentation and antigen Uptake 
assays
Antigen presentation assays were performed as previously 
described (38). Briefly, ovalbumin (OVA) (10  µg/mL; Sigma 
A7641) pulsed cDCs were stimulated with or without TLR agonists 
for 4 h. OT-I CD8+ T cells and OT-II CD4+ T cells were purified 
and then labeled by carboxyfluorescein diacetate succinimidyl 
ester (CFSE) (1 µM; Molecular Probes C34554). CD8+ cDCs were 
cocultured with OT-I CD8+ T cells for 60  h, whereas CD11b+ 
cDCs were cocultured with OT-II CD4+ T cells for 96  h, both 
in the presence of granulocyte-macrophage colony-stimulating 
factor (GM-CSF) (20  ng/mL; Peprotech 315-03). Proliferated 
OT-I or OT-II T cells were defined as diluted CFSE signal ana-
lyzed by flow cytometry. The numbers of T cells were counted by 
AccuCheck counting beads (Molecular Probes PCB100). Antigen 
uptake ability of DCs was examined by endocytosis analysis 
of Alexa Fluor 488 (AF488)-conjugated OVA protein (5  µg/
mL; Molecular Probes O-34781) as described previously (39). 
DCs were incubated with OVA-AF488 (5 µg/mL) at 37°C or on 
ice (negative control) for 30 min. Cells were washed twice with 
cold medium and analyzed by flow cytometry.
Tlr activation and cytokine Detection
Splenic DCs (5  ×  105 cells/mL) were stimulated by Pam3 
(200 nM), SUP3 (200 nM), or CpG ODN 1668 (20 nM; Adipogen 
IAX-200-001) in the GM-CSF (20  ng/mL) supplemented 
medium for indicated periods. Cell culture supernatants were 
harvested at indicated time points and stored at −40°C. RAW 
264.7 cells and GMDCs were stimulated by lipopolysaccharide 
(LPS) (20 ng/mL; Adipogen IAX-100-013), Pam3, or SUP3 (both 
at 200 nM) for 24 h. For in vivo administration, Pam3 (2 nmol per 
mouse), SUP3 (2 nmol per mouse), or LPS (1 µg per mouse) were 
intravenously (i.v.) injected via tail veins. Serum was obtained 
through tail vein bleeding and centrifuged after coagulation and 
stored at −40°C. Cytokines (IL-6, eBioscience 88-7064; TNFα, 
eBioscience 88-7324; IL-12p40, BioLegend 431604), chemokine 
(MIP1α, R&D Systems DY450-05), and total IgM (eBioscience, 
88-50470) were quantified by ELISA kits following the instruc-
tions of manufacturers.
immunoblot analysis
Immunoblot assay was performed as described elsewhere 
(40, 41). Briefly, whole-cell lysates were prepared by direct lysis 
in SDS loading buffer. Lysates were separated by 10% SDS-
PAGE and transferred to a polyvinylidene fluoride membrane 
(Millipore IPVH00010) for probing with antibody. Antibodies 
against phosphorylated NF-κB p65 (p-p65) (Ser 536) (Clone 
93H1), p-SAPK/JNK (Thr183/Tyr185) (Clone 81E11), SAPK/
JNK (Clone 56G8), p-p38 (Thr180/Tyr182) (Clone 3D7), and p38 
(Clone D13E1) were purchased from Cell Signaling Technology. 
Antibodies against IκBα (Clone 93H1), p-ERK (Clone E-4), and 
ERK (Clone K-23) were purchased from Santa Cruz Biotech. The 
chemiluminescence signals were captured by Amersham Image 
600 system (GE Healthcare).
OVa-coated splenocytes (Ocs) 
immunization
Splenocytes were X-ray irradiated (1500 Rad) and then coated 
with OVA (1  mg per spleen) in RPMI 1640 medium (Gibco 
11875-119) for 30  min at 37°C. Cells were washed twice with 
RPMI 1640 medium. Then OCS (2 × 107 cells per mouse) were 
i.v. injected through tail vein, together with or without Pam3 
(2 nmol per mouse) or SUP3 (2 nmol per mouse). Seven days 
post-immunization, OVA-specific CD8+ T cells in spleen were 
analyzed by flow cytometry by staining with fluorescence-con-
jugated antibodies against CD19 (eBioscinece, clone 1D3), CD3 
(eBioscinece, clone 145-2C11), CD8 (eBioscinece, clone 53-6.7), 
and SIINFEKL/H-2Kb-Pentamer (ProImmune F093-4A).
Tumor Model
Tumor model was applied as previously described with some 
modifications (42). Briefly, mice were immunized by OCS 
alone, OCS with Pam3 (2 nmol per mouse), or OCS with SUP3 
(2 nmol per mouse) for 30 days. Then mice were i.v. injected with 
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OVA-expressing B16 melanoma cells (B16-OVA) (5 × 105 cells 
per mouse). After 16 days, the numbers of metastatic tumors in 
lung were counted.
OT-ii activation In Vivo
Carboxyfluorescein diacetate succinimidyl ester-stained OT-II 
CD4+ T cells (2 × 106 cells per mouse) were transferred into mice 
1 day prior immunization. Then the recipients were subcutane-
ously (s.c.) injected with OVA alone (100 µg per mouse), or OVA 
mixed with SUP3 (2  nmol per mouse) or Pam3 (2  nmol per 
mouse) at groin. Three days after immunization, OT-II CD4+ T 
cells from inguinal lymph nodes were analyzed by flow cytometry.
Thymus-Dependent (TD) antigen 
immunization and antibody Titer analysis
Thymus-dependent antigen immunization and antibody titer 
analysis were performed as previously described (43). Briefly, 
wild-type (WT) mice were immunized by i.p. injection of TD 
antigen nitrophenyl-keyhole limpet hemocyanin (NP-KLH, 5 µg 
per mouse; Biosearch Technologies N-5060) alone, or mixed with 
SUP3 (2 nmol per mouse), Pam3 (2 nmol per mouse), or alum 
(3  µg per mouse; Thermo 77161). Serum was harvested every 
week, and nitrophenyl-specific IgM and IgG were determined by 
ELISA. IgM and total IgG were captured by nitrophenyl 30mer 
(Biosearch Technologies N-5050H), and high affinity IgG was 
captured by nitrophenyl 8mer (Biosearch Technologies N-5050L) 
pre-coated ELISA plates (Corning 9018).
antigen Deposition
Wild-type mice were s.c. injected with OVA-AF647 alone 
(25  µg per mouse; Molecular Probes O-34784), or mixtures of 
OVA-AF647 with SUP3 (2 nmol per mouse) or Pam3 (2 nmol 
per mouse) at groin. Inguinal lymph nodes were isolated 24  h 
post-injection, and then immune cells were analyzed by flow 
cytometry.
statistical analysis
Data were analyzed by ANOVA followed by Bonferroni multiple 
comparison test or by unpaired, two-tailed Student’s t test with 
GraphPad Prism 5. Data were presented as mean ± SD or ± SEM, 
and p < 0.05 (*) was considered statistically significant.
resUlTs
Design of Tlr2 agonist sUP3
Pam3 is a lipopeptide and serves as a TLR2 agonist through bind-
ing to TLR2/TLR1 heterodimer. Although Pam3 is widely used 
as a TLR2 agonist, some intrinsic problems remain in detailed 
mechanism studies and drug development. The two ester groups 
of Pam3 can be easily hydrolyzed in plasma, and the hydroxyl 
group in serine could be readily oxidized in physiological con-
ditions (Figure S1A in Supplementary Material). All of these 
facts made Pam3 less stable in  vivo. In order to overcome the 
disadvantages of the current existing TLR2 ligands, we designed 
a new TLR2 agonist that should be chemically and metabolically 
more stable. Based on the structural features of Pam3 and 
TLR1/2 receptors co-crystal, we replaced the two ester-linked 
palmitoyl groups with chemically more stable bioisostere, 
carbamate-linked C14 groups (Figures S1A,B in Supplementary 
Material). In addition, we displaced serine residue in Pam3 with 
glycine residue to eliminate this chiral center (Figures S1A,B 
in Supplementary Material). Since the third lysine residue in 
Pam3 is crucial for H bonding, we kept three lysine residues 
in the new molecule and removed the forth lysine residue to 
further reduce the molecular weight of the new TLR2 agonist, 
(2S,5S,8S,14R,18R)-2,5,8-tris(4-aminobutyl)-4,7,10,13,21-
pentaoxo-14-palmitamido-18-((tetradecylcarbamoyl)oxy)-
20-oxa-16-thia-3,6,9,12,22-pentaazahexatriacontan-1-oic acid. 
It is termed SUP3 (Figure 1A; Figures S1A,B in Supplementary 
Material). Chemical characterization of SUP3 by 1H nuclear 
magnetic resonance and electrospray ionization mass spec-
trum analysis further confirm the structure (Figures S2A,B in 
Supplementary Material). The affinity of SUP3 is comparable 
with Pam3 (Figure S3A in Supplementary Material), whereas the 
plasma stability of SUP3 is much higher than Pam3 (Figure S3B 
in Supplementary Material).
To validate the specificity of SUP3 for TLR2, we gener-
ated Tlr2−/− RAW 264.7 cells with CRISPR-Cas9 system 
(Figure 1B). Both Pam3 and SUP3 stimulation induced large 
amount of TNFα production by WT RAW cells, indicating 
that SUP3 could function similarly as Pam3 in triggering TLR2 
response (Figure  1C). TLR2 deficiency abolished the effect 
of Pam3 and SUP3 on RAW cells, evidenced by no secretion 
of TNFα by Tlr2−/− RAW cells upon challenge by Pam3 and 
SUP3 (Figure 1C). It demonstrated that TLR2 was the recep-
tor for SUP3. To further determine the bioactivity of SUP3 as 
a TLR2 agonist, we determined the cytokine production by 
GMDCs upon TLR2 stimulation. GMDCs were generated from 
bone marrow cells cultured in the presence of GM-CSF and 
interleukin-4 (44, 45). It has been demonstrated that GMDCs 
are potent pro-inflammatory cytokine producers upon TLR 
stimulation and GMDCs express TLR2 and respond to TLR2 
ligands. We found that SUP3 exhibit equal ability as Pam3 in 
activating GMDCs, as the production of IL-6 and TNFα were 
comparable by GMDCs upon stimulation by SUP3 and Pam3 
(Figure 1D). Taken together, these data suggested that SUP3, 
the newly designed TLR agonist, engaged TLR2 specifically as 
well as Pam3.
sUP3 induced More Vigorous cTl 
responses Than Pam3 without excessive 
Production of inflammatory cytokines 
In Vivo
The consequence of immunization or vaccination is the acquire-
ment of preventive or therapeutic effects on infections or tumors, 
via generating antigen-specific adaptive immune responses and 
memory. Elimination of tumors or intracellular infection requires 
antigen-specific CD8+ CTLs, the major executors in cellular 
immunity (46, 47). In mice, the differentiation and activation 
of CD8+ CTL is launched through antigen cross-presentation 
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stimulation with lipopolysaccharide (LPS) (1 µg/mL), Pam3CSK4 (Pam3 hereafter) (500 nM), or SUP3 (500 nM) for 8 h. (D) GMDCs were generated by culturing 
bone marrow cells with granulocyte-macrophage colony-stimulating factor and interleukin-4 for 7 days, then activated by LPS (20 ng/mL), Pam3 (200 nM), or SUP3 
(200 nM) for 24 h. The production of cytokines IL-6 and TNFα in culture supernatant was determined by ELISA. *p < 0.05, ****p < 0.0001, “n.s.” indicates 
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by CD8+ cDC (46, 47). Some TLR agonists have been shown to 
enhance antigen cross-presentation by cDCs and the subsequent 
CD8+ T cell activation (30, 35, 48–51). To investigate whether 
SUP3 has an effect on CTL responses, we determined the activity 
of SUP3 in antigen-specific cellular immunity. Mice were immu-
nized by intravenous injection of OVA coated splenocytes (OCS), 
as these cell-associated OVA antigens can be cross-presented 
efficiently by CD8+ cDC to CD8+ T cells (52). Seven days post-
immunization, the percentages of OVA antigen-specific CD8+ 
T cells in spleens were determined by pentamer (SIINFEKL/ 
H-2Kb) staining. The effects of various doses of SUP3 and Pam3 
on the induction of CTL were determined and 2 nmol was selected 
as the optimal dose in the following assays (Figures S4A,B in 
Supplementary Material). Administration of SUP3 at a high dose 
of 10  nmol resulted in decreased CTL induction and enlarged 
spleens, whereas treatment with Pam3 at the same dose did not 
have the same effect (data now shown), indicating that SUP3 was 
much more potent than Pam3 and the mice could not tolerate 
such a high dose of agonists. We found that OCS formulated with 
SUP3 induced significantly more antigen-specific CD8+ T cells 
than that with Pam3 in vivo (Figures 2A,B). To further determine 
whether the enhanced CTL activation by SUP3 can lead to more 
vigorous antitumor activity, we immunized mice as described 
above and then challenged by intravenous inoculation of OVA-
expressing B16 melanoma cells (B16-OVA) (53). We found that 
mice immunized with OCS and SUP3 showed markedly reduced 
number of tumors in the lungs compared to those with OCS alone 
or OCS with Pam3 16 days after the challenge (Figures 2C,D). It 
indicated that immunization with SUP3 conferred more efficient 
CTL responses, thus more effective protection against tumor 
formation. Taken together, these results demonstrated that SUP3 
was far more effective than Pam3 in inducing CTL responses 
in vivo.
Sustainable stimulation by TLR agonists such as LPS, often 
lead to elevated inflammatory cytokines in vivo, which may result 
in severe adverse reactions. To test whether this is also the case for 
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lipopolysaccharide (LPS) (1 µg per mouse) for 1 h, the serum was collected, and the levels of different cytokines were determined by ELISA. “n.d.” indicates “not 
detected.” *p < 0.05, **p < 0.01.
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SUP3 and Pam3, we determined the level of serum inflammatory 
cytokines upon SUP3 or Pam3 administration. The inflammatory 
cytokines including IL-6, TNFα, and IL-12p40 and chemokine 
MIP1α were all maintained at low levels even after SUP3 or Pam3 
stimulation (Figure  2E), suggesting that both SUP3 and Pam3 
acted as mild TLR agonists for inflammatory responses. Overall, 
SUP3 promoted stronger CTL response without inducing exces-
sive inflammatory cytokine production, suggesting that SUP3 
could function as a better adjuvant than Pam3 with potential for 
clinical applications.
sUP3 enhanced cross-Presentation of 
OVa antigen by cD8+ cDcs In Vitro
Cytotoxic T lymphocyte is one of the major effector cell types 
in cellular immunity, which can be induced by CD8+ cDCs via 
antigen cross-presentation to naïve CD8+ T cells (11, 13, 14, 47). 
It is well known that TLR activation can enhance the function of 
DCs (54). It is likely that SUP3 promoted stronger CTL responses 
through enhancing the function of CD8+ cDCs. To investigate 
whether SUP3 played any roles in antigen cross-presentation 
by splenic CD8+ cDCs and the subsequent activation of naïve 
CD8+ T cells, we examined the antigen cross-presentation capac-
ity of CD8+ cDCs with or without SUP3 by using OVA protein 
antigen and the OVA-specific T cell receptor (TCR) transgenic 
OT-I CD8+ T cells. The CD8+ cDCs pulsed with OVA peptide 
SIINFEKL specifically recognized by OT-I T cells were used as 
positive control. SIINFEKL peptide pulsed CD8+ cDCs presented 
antigen peptide directly without antigen processing and induced 
strong OT-I T cell proliferation (Figure 3A). Upon stimulation of 
OVA protein pulsed CD8+ cDCs by TLR2 agonists, the prolifera-
tion of cocultured OT-I cells increased significantly, evidenced 
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7
Guo et al. Function of Novel TLR2 Agonist
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 158
by increased numbers of divided OT-I T cells (Figures  3A,B) 
and enhanced production of IFN-γ (Figure  3C) compared 
to that without stimulation by TLR2 agonists. These results 
indicated that SUP3 and Pam3 were comparable in enhancing 
cross-presentation by CD8+ cDCs in  vitro, thus leading to 
enhanced antigen-specific CD8+ T cell activation. It is interesting 
to note that unlike the results described above, in which SUP3 
induced much stronger antigen-specific CD8+ T cell proliferation 
and antitumor CTL responses in vivo, SUP3 and Pam3 induced 
similar levels of OVA-specific CD8+ T cell activation in  vitro. 
This difference is likely due to the improved stability of SUP3 
compared to Pam3 in vivo.
Exogenous antigens are internalized, degraded into short 
peptides, uploaded onto MHC-I and finally transported to cell 
surface for recognition by cognate T cells (55–57). The first step of 
antigen presentation is internalization of extracellular materials. 
To clarify whether antigen uptake process is affected by TLR2 
engagement, we determined the endocytosis of fluorescence-
conjugated soluble OVA (OVA-Alexa Fluor 488, OVA-AF488) by 
CD8+ cDCs. The results showed that the uptake of OVA by CD8+ 
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cDCs was not influenced by TLR2 activation (Figures  3D,E), 
indicating that enhanced antigen presentation by CD8+ cDCs was 
not due to facilitated antigen uptake process.
sUP3 Upregulated expression of 
costimulatory Molecules on cD8+ cDcs 
and induced low level Production of 
inflammatory cytokines
Costimulatory molecules, which serve as the second signal 
for T cell activation, can be efficiently upregulated upon TLR 
activation. To investigate whether SUP3 affected the expression 
of costimulatory molecules on CD8+ cDCs, we stimulated puri-
fied DCs by SUP3 or Pam3 in vitro and stained with antibodies 
to costimulatory molecules as well as MHC molecules. We 
found that both SUP3 and Pam3 induced substantial upregula-
tion of CD40, CD80, CD86, and MHC-II on CD8+ cDCs, but 
not MHC-I (Figure  4A), demonstrating that SUP3 induced 
effective costimulation as well as Pam3 in vitro. We then tested 
whether SUP3 had similar effects on splenic CD8+ cDCs in vivo. 
Upon in vivo administration of SUP3 or Pam3 via intravenous 
(i.v.) route, the expressions of CD40 and CD86 increased on 
splenic CD8+ cDCs from both SUP3- or Pam3-treated mice, 
indicating the ability of SUP3 to promote DC activation in vivo 
(Figure 4B).
Toll-like receptor stimulation is required for functional 
maturation of DCs, which is essential for T cell activation and 
initiation of adaptive immunity. Antigen recognition without 
danger signals like TLR ligands leads to tolerance but not 
antigen processing for subsequent presentation (17, 58). It is 
well established that TLR-induced activation of nuclear factor-
kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) 
signaling events contribute to activation of responding cells. To 
determine whether SUP3 could activate classical Toll-dependent 
signaling pathways in CD8+ cDCs, we treated purified CD8+ 
DCs by TLR2 agonists at various time points (0–120 min) and 
detected the expression of the relevant signaling molecules and 
their phosphorylated forms by immunoblotting. We found SUP3 
stimulation induced phosphorylation of p65 and degradation of 
IκBα and enhanced phosphorylation of ERK, JNK, and p38 in 
CD8+ cDCs (Figure 4C), indicating that similar to Pam3, SUP3 
was able to induce activation of NF-κB and MAPK pathways. 
Taken together, SUP3 could induce activation of canonical TLR 
signaling events in CD8+ cDCs.
In addition to costimulation, secretion of cytokines by DCs is 
another major feature of DC activation upon TLR engagement. 
Cytokines like bioactive IL-12p70 predominately produced by 
CD8+ cDCs drive functional differentiation of activated T cells 
and provide the third signal for DC-induced T cell activation (59). 
As SUP3 could facilitate CD8+ T cell activation (Figures 3A–C), 
we therefore examined whether SUP3 could induce inflamma-
tory cytokines production by CD8+ cDCs. We activated purified 
CD8+ cDCs by SUP3, Pam3, or CpG in vitro and quantified the 
amounts of cytokines in the supernatant by ELISA. Interestingly, 
in contrast to CpG stimulation which induced large amount of 
IL-12p70, IL-6, and TNFα production by CD8+ cDCs, SUP3 
and Pam3 induced no IL-12p70 and only low levels of IL-6 and 
TNFα (Figure 4D). These results demonstrated that SUP3 acted 
as a mild agonist in inflammatory responses. Collectively, our 
results demonstrated that SUP3 acted as an efficient enhancer of 
antigen cross-presentation by CD8+ cDCs through upregulating 
surface costimulatory molecules and promoting activation of 
NF-κB and MAPK signaling pathways, without inducing large 
amount of inflammatory cytokines. Thus, SUP3 fulfilled the 
properties of a good adjuvant with strong immunostimulatory 
capacity for T cell activation and minimal induction of inflam-
matory response.
sUP3 enhanced cD4+ T cell activation 
and Production of antibodies against TD 
antigens
In addition to cellular immunity, the other arm of adaptive 
immunity is humoral immunity mediated by antibodies. 
Production of TD antigen-specific antibodies requires the assis-
tance of Th2 subtypes, which is mainly induced by CD11b+ cDCs 
(15, 60, 61). Exogenous antigens are routinely presented via 
MHC-II pathway by CD11b+ cDCs and ultimately recognized 
by CD4+ T cells for helper T cell differentiation (11). CD11b+ 
cDCs expressed comparable levels of TLR2 to that of CD8+ cDCs 
(Figure S5A in Supplementary Material). We predicted that 
SUP3 might enhance the functions of CD11b+ cDCs thus Th2-
mediated production of TD antigen-specific antibodies. To test 
this hypothesis, we immunized mice via intraperitoneal (i.p.) 
injection of TD antigen NP-KLH with or without TLR agonists. 
Formulation with alum was regarded as positive control in this 
setting, as alum is always used as an efficient adjuvant in anti-
body induction. Serum antibody titers were determined every 
week post-immunization. As expected, SUP3 induced higher 
titers of TD antigen-specific antibodies including IgM, total IgG 
and high affinity IgG than Pam3 did (Figure  5A). This result 
suggested that SUP3 remained functioning for a longer time 
than Pam3 in  vivo, thus resulting in higher levels of antibody 
production.
As mentioned above, CD4+ Th2 cells polarized by CD11b+ 
cDCs are critical in TD antigen-specific antibodies production. 
Thus, SUP3 might enhance TD antibody production via facilitat-
ing CD4+ T cell activation in vivo. To test this hypothesis, purified 
CD4+ OT-II T cells from spleens of OVA-specific TCR transgenic 
mice were labeled by CFSE and transferred into WT mice for 
1 day, followed by subcutaneous (s.c.) immunization with soluble 
OVA proteins with TLR agonists for another 3 days. Treatment 
with SUP3 induced more proliferation of OT-II CD4+ T cells 
than that with Pam3 in draining lymph nodes (Figures 5B,C), 
demonstrating the ability of SUP3 to induce stronger CD4+ T 
cell activation in vivo, thus leading to enhanced TD antibodies 
production.
sUP3 Facilitated antigen Presentation by 
cD11b+ cDcs In Vitro
As CD4+ T cell activation is enhanced upon SUP3 treatment, we 
speculated that SUP3 functioned through improving functions 
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of CD11b+ cDCs. To test this speculation, we evaluated OVA 
antigen presentation by SUP3 pretreated CD11b+ cDCs to OT-II 
CD4+ T cells. An enhanced OT-II CD4+ T cell proliferation was 
observed upon stimulation of CD11b+ cDCs by SUP3 in  vitro 
(Figures  5D,E), indicating that SUP3 strengthened antigen 
presentation ability of CD11b+ cDCs. The maturation of CD11b+ 
cDC is marked by upregulation of costimulatory molecules. 
Intravenous administration of SUP3 and Pam3, both induced 
maturation of splenic CD11b+ cDC indicated by CD86 upregula-
tion (Figure 5F). Furthermore, similar to CD8+ cDCs, CD11b+ 
cDCs produced lower level of IL-6, TNFα, and MIP1α upon 
stimulation by SUP3 and Pam3, implying a weak ability of SUP3 
in inducing inflammatory responses (Figure 5G).
Collectively, these results demonstrated that SUP3 facilitated 
antigen presentation by CD11b+ cDCs and subsequent activation 
of OT-II CD4+ T cells, which led to higher levels of TD antibody 
production in vivo. These observations again demonstrated the 
physiological advantages of SUP3 over Pam3 as an immune 
adjuvant.
sUP3 enhanced antigen Deposition  
in aPcs in Draining lymph nodes
As immune adjuvants enhance immunogenicity of simultane-
ously administrated antigens via increasing antigen deposition 
in lymph nodes, and prolonging antigen presentation (62, 63), we 
proposed that SUP3 might prolong the duration of antigen depo-
sition in draining lymph nodes. To test this, we s.c. immunized 
mice with OVA-AF647 at groin, or co-administrated with either 
SUP3 or Pam3 for 24 h. Antigen deposition in various immune 
cell populations from inguinal lymph nodes was then assessed. 
After immunization of OVA with SUP3, increased numbers of 
antigen-containing CD8+ cDCs, CD11b+ cDCs, macrophages, 
and monocytes were observed compared to those with OVA alone 
or OVA with Pam3 (Figures 6A,B). Moreover, the total number 
of cells containing antigens increased more upon administration 
of SUP3 over Pam3 (Figure 6B). This finding indicated that SUP3 
facilitated antigen deposition in cDCs, macrophages and mono-
cytes in draining lymph nodes, thus contributed to enhanced 
T cell activation.
sUP3 Directly Promoted stronger B cell 
activation In Vitro
B lymphocytes can function as APCs that directly respond to 
invading pathogens through recognition via innate sensors. 
In addition to myeloid cells including DCs, macrophages, and 
monocytes, B cells are only lymphocytes positive for TLR2 
(Figure S5A in Supplementary Material). TLR ligation on B 
cells drives fast IgM production to eliminate pathogens before 
the formation of effective antibody-mediated adaptive immu-
nity, which requires 5–7  days to develop (64). The direct TLR 
triggered IgM production by B cells, as a thymus independent 
(TI) pathway, compensates the delayed formation of humoral 
immunity to control pathogens. To evaluate B cell response to 
SUP3, we analyzed the expression of activation markers and 
production of IgM upon treatment by SUP3 in vitro. Engagement 
of TLR2 by SUP3 and Pam3 induced marked upregulation of 
CD25, CD40, and CD86 on B lymphocytes (Figure 7A), imply-
ing a direct effect of SUP3 on B cell activation. In addition, more 
antigen-independent production of IgM was induced by SUP3 
than that induced by Pam3 (Figure 7B), indicating that SUP3 
could induce a stronger and longer lasting B cell response than 
Pam3. This finding is in line with the better stability of SUP3 
compared to Pam3. Our results demonstrated that TLR2 agonists 
could enhance B cell function not only in T cell-dependent but 
also in T-independent manners.
DiscUssiOn
Our newly designed TLR2 agonist SUP3 is structurally similar 
to classical TLR2 ligand Pam3. The chemical modification by 
replacing oxygen with nitrogen in Pam3 stabilizes the covalent 
bonds between glycerol backbone and palmitic acid chains. In 
addition, glycine instead of lysine reduces the chiral center and 
further simplifies the structure. These improvements overcome 
current disadvantages of Pam3, such as weak stability and 
structural complexity. Meanwhile, the specificity and affinity to 
TLR2 and bioactivity to promote TLR2-dependent cytokines are 
retained. Moreover, the peptide components of SUP3 make it 
easy and convenient to be conjugated with antigenic peptides. 
This type of conjugation could easily confer adjuvant activity 
to the conjugated antigens and induce markedly enhanced 
immune responses toward antigens without additional adjuvant 
formulations (6, 25, 65, 66). Intriguingly, this special feature is 
not shared with any other TLR agonists except those of TLR2. 
Adjuvants of vaccines are defined as components capable of 
enhancing and shaping antigen-specific immune responses (1). 
Ideal adjuvants should possess properties including safety and 
effectiveness with defined and well-controlled functions (1). 
An effective adjuvant should help to reduce required dose of 
antigens or the number of immunizations and have significant 
improvement in antibody- as well as cell-mediated immune 
responses (1). Although both SUP3 and Pam3 possess these 
features of an ideal adjuvant, SUP3 is chemically more stable 
and structurally simpler than Pam3. SUP3 also exhibited clear 
advantages compared to Pam3 in biological activities, suggesting 
that SUP3 could be a good substitution of Pam3 in vaccinations 
and cancer treatment.
Recognition of microbial or viral components by PRRs on 
DCs elicits immediate host response and ultimately long-lasting 
adaptive immunity (17). DCs are one of the first encounters for 
non-self components, such as pathogens and tumor antigens. 
The initial responses of DCs to these pathogens determine the 
shape of adaptive immunity. Thus DCs occupy an indispensable 
position in orchestrating immune responses to eliminate patho-
gens and tumors. Consequently, immune modulations targeting 
DCs could be an effective strategy to harness immune system to 
endow protective immunity. Cancer immunotherapy with DCs is 
favorable due to fewer side effects, although with limited benefit 
observed from recent studies (67).
Enhancement of adaptive immunity is a key parameter of 
adjuvants in the context of vaccines. Shaping adaptive immunity 
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always requires several days of time. In this study, we observed 
that more antigen-specific CTLs were generated in the presence of 
SUP3 than that with Pam3 during the induction of effector T cell 
differentiation by OCS in vivo. Consistent with this observation, 
the presence of SUP3 induced much stronger protective response 
against tumor challenge, as revealed by significantly reduced 
tumor formation in the lungs. Those effects of SUP3 could be 
achieved through enhancing antigen cross-presentation by CD8+ 
cDCs, which are responsible for CTL induction and subsequent 
clearance of tumor cells. SUP3 significantly enhanced the surface 
expression of costimulatory molecules on cDCs, providing one 
of the essential signals for T cell activation. Intriguingly, SUP3 
enhanced antigen cross-presentation by CD8+ cDCs was accom-
panied by a low to moderate levels of inflammatory cytokines, 
which is different from effects of many other TLR agonists used as 
adjuvant such as LPS. This functional feature of SUP3 can be con-
sidered as an advantage for a good adjuvant, as over production of 
inflammatory cytokines could be detrimental. Altogether, SUP3 
can serve as a potential adjuvant in therapeutic or prophylactic 
vaccines.
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Antigen-specific antibody-mediated humoral immunity is 
the other arm of adaptive immunity. Indeed, SUP3 not only 
enhances CTL-mediated cellular immunity but also facilitates 
the production of various types of specific antibodies to TD 
antigens. As mentioned previously, TD antibody production 
requires effector CD4+ T cells activated through MHC-II 
antigen presentation pathway mainly promoted by CD11b+ 
cDCs. Addition of SUP3 enhanced antigen presentation 
ability of CD11b+ cDCs in in vitro assays and administration 
of SUP3 enhanced CD4+ T cell activation in vivo. Thus, SUP3 
induced more antibody production than Pam3 in T-dependent 
manner through enhancing antigen presentation by CD11b+ 
cDCs. Moreover, an enhanced TI antibody production by B 
cells was also observed after SUP3 administration. B cells are 
capable of recognizing and responding to pathogens directly 
via innate immune receptors like TLR. TLR activation of B 
cells could ultimately result in IgM secretion, which rapidly 
neutralizes pathogens, namely the TI antibody response 
(68). In this study, SUP3 directly promoted IgM production 
by B cells, suggesting its effects on both innate and adaptive 
immunity. Overall, SUP3 enhanced cellular immunity as well 
as TD and TI antibody production. This functional property of 
SUP3 made it a promising ideal adjuvant in immunotherapy 
and vaccination.
The more vigorous immune stimulatory activities of SUP3 
compared to Pam3 in CTL induction, rejection of B16-OVA 
tumors, CD4+ T cell activation, and the production of TD anti-
bodies could all attribute to its better stability and sustainable 
activity over Pam3 in vivo. Thus, SUP3 could act as an effective 
adjuvant in immunization.
An ideal adjuvant should have minimum or even none 
adverse effects. Generally, TLR agonists are potent immune 
stimuli capable of inducing large amount of inflammatory 
cytokines, which may lead to cytokine storm to damage the 
hosts before inducing protective immune responses. Our study 
and previous studies showed that engagement of TLR2 by triacyl 
lipopeptides did not promote severe inflammatory responses, 
which would be beneficial for its clinical applications (65, 69, 
70). Ligation of TLR2 also activated PI3K–Akt–β-catenin axis 
to induce IL-10 expression, which is a regulatory cytokine to 
suppress inflammation (70). TLR2 agonists cloud also induce 
rapid degradation of IRAK1, which is an essential component 
of inflammatory response (71). These effects might contribute to 
the weaker inflammatory properties of TLR2 agonists. In addi-
tion, TLR2 ligation signal via adaptor MyD88 to promote down-
stream events, whereas LPS recognition by TLR4 can activate 
both MyD88 and TRIF adaptors mediated pathways (72, 73). 
Thus, LPS could induce stronger inflammatory responses via 
two pathways than that induced by TLR2 agonists. Meanwhile, 
this immune regulatory effect did not attenuate T cell activation 
by DCs (74). Again, SUP3 could be considered as a novel effec-
tive immune adjuvant.
Adjuvants are not only applied in vaccination but also in 
cancer immunotherapy. CTLs induced by DCs are major knights 
to combat tumors. Enhanced DC activation will lead to vigorous 
antitumor cytotoxicity by CTLs. Our studies proved that SUP3 
conferred more protective immunity from tumor metastasis to 
the lungs. Tumors escape from immune attack by diminishing 
CTL responses. PD-1/PD-L1 is important check-point molecules 
during immune responses, which suppress antitumor immune 
responses. Blocking and eliminating their inhibitory effects 
by neutralizing antibodies significantly enhanced antitumor 
immune responses and had been used in clinical trials for cancer 
therapies (75–77). However, this treatment is not always effective 
for some patients due to various reasons. A combination of an 
effective immune adjuvant together with anti-PD-1/PD-L1 anti-
bodies may improve the efficacy of the treatment. Our synthetic 
TLR2 agonist SUP3 could be an outstanding candidate for this 
purpose. Further tests are needed to determine the effectiveness 
of this strategy.
Overall, in this study, we developed a novel TLR2 agonist 
SUP3, which is more stable than Pam3 and could enhance DC 
functions without inducing excessive inflammation, the most 
favorable property of an ideal adjuvant. As DCs are essential 
initiators of antigen-specific immune responses, the enhanced 
activation and function of DCs by TLR2 agonists should improve 
immune responses to pathogens or tumors. Our study suggested 
that the new TLR2 agonist SUP3 could be a promising adjuvant 
in vaccination and immune modulations.
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